Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hubbell Inc
NYSE:HUBB
|
US |
Bioventus Inc
Stock-Based Compensation
Bioventus Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Stock-Based Compensation
$31.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Stock-Based Compensation
$55.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Stock-Based Compensation
$185.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Stock-Based Compensation
$85.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
43%
|
CAGR 10-Years
46%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Stock-Based Compensation
$43.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
25%
|
CAGR 10-Years
35%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
